Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial

Kasiri et al., Journal of Investigative Medicine, doi:10.1177/10815589221141815, IRCT20190804044429N5
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Mortality 7% Improvement Relative Risk Ventilation 7% ICU admission -24% Recovery, day 14 28% Recovery, day 7 12% Recovery time 14% Colchicine  Kasiri et al.  LATE TREATMENT  DB RCT Is late treatment with colchicine beneficial for COVID-19? Double-blind RCT 110 patients in Iran (February - May 2021) Improved recovery with colchicine (not stat. sig., p=0.59) c19early.org Kasiri et al., J. Investigative Medicine, Jan 2023 Favors colchicine Favors control
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Very late treatment (10 days from onset) RCT 110 patients in Iran, showing no significant difference in outcomes with colchicine. Colchicine 2mg loading dose followed by 0.5mg bid for 7 days.
risk of death, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of mechanical ventilation, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of ICU admission, 23.6% higher, RR 1.24, p = 0.63, treatment 12 of 55 (21.8%), control 9 of 51 (17.6%).
risk of no recovery, 27.9% lower, RR 0.72, p = 0.59, treatment 7 of 55 (12.7%), control 9 of 51 (17.6%), NNT 20, day 14.
risk of no recovery, 11.7% lower, RR 0.88, p = 0.69, treatment 20 of 55 (36.4%), control 21 of 51 (41.2%), NNT 21, day 7.
recovery time, 14.3% lower, relative time 0.86, p = 0.06, treatment 55, control 51.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kasiri et al., 16 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, mean age 54.6, 6 authors, study period February 2021 - May 2021, average treatment delay 10.0 days, trial IRCT20190804044429N5. Contact: ghazaeianm@gmail.com.
This PaperColchicineAll
The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
Hossein Kasiri, Mobin Ghazaiean, Nima Rouhani, Fahimeh Naderi-Behdani, Monireh Ghazaeian, Robabeh Ghodssi-Ghassemabadi
Journal of Investigative Medicine, doi:10.1177/10815589221141815
This study was designed to evaluate the effects of colchicine in the improvement of clinical outcomes of hospitalized COVID-19 patients. This prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on adult patients (.18 years) with severe COVID-19. The included patients were randomly (1:1) assigned to the colchicine (2 mg loading dose followed by 0.5 mg twice daily for 7 days) or placebo group. Both groups received remdesivir and interferon beta-1b. The primary outcome of the study was to receive clinical response as ordinal scale of 1 or 2. Secondary outcomes were hospital complications and 28-day mortality. Between February and May 2021, 110 patients were included and 106 of them were analyzed. Baseline clinical characteristics and demographics were not significantly different. According to the ordinal scale, 30 patients in the control group (58.8%) responded to treatment within 7 days, while 35 patients (63.6%) in the colchicine group showed the same response (p = 0.61, odds ratio (OR) = 1.23, 95% CI [0.560-2.68]). On the 14th day, 87.3% of the colchicine group (n = 48) and 82.4% of the control group (n = 42) responded (p = 0.48, OR = 1.47, 95% CI [0.50.3-4.29]. In addition, 28-day mortality, intensive care unit admission, and hospital duration were not different between the groups (p = 0.99, 0.59, 0.06). Diarrhea and nausea were the major side effects dominant in the colchicine group. Colchicine showed no beneficial effects on clinical improvement and hospital complications in patients with COVID-19. Moreover, in case of prescription, the safety concerns of colchicine, specially gastrointestinal side effects, should be taken into account.
Authors' contributions Hossein Kasiri and Mobin Ghazaiean: Data Curation, Investigation. Nima Rouhani: Project Administration. Fahimeh Nader-behdani: Writing-original draft. Monireh Ghazaeian: Conceptualization, Methodology, Supervision, Writing-review & editing. Robabeh Ghodssi-Ghassemabadi: Formal analysis and Data Curation. Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Ethics approval This study abides by the Declaration of Helsinki and was approved by the Ethics Committee of Mazandaran University of Medical Sciences (IR.MAZUMS.REC.1399.914). Supplemental material Supplemental material for this article is available online.
References
Ali, Baloch, Ahmed, The outbreak of coronavirus disease 2019 (COVID-19)-an emerging global health threat, J Infect Public Health
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Buonaguro, Puzanov, Ascierto, Anti-IL6R role in treatment of COVID-19-related ARDS, J Transl Med
Cao, Li, COVID-19: towards understanding of pathogenesis, Cell Res
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Garcı´a, Mancilla-Galindo, Paredes-Paredes, Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome, Future Virol
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Madsen, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Manenti, Maggiore, Fiaccadori, Reduced mortality in COVID-19 patients treated with colchicine: results from a retrospective, observational study, PLoS One
Montealegre-Go´mez, Garavito, Go´mez-Lo´pez, Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients, Reumatol Clin
Nasiripour, Zamani, Farasatinasab, Can colchicine as an old anti-inflammatory agent be effective in COVID-19?, J Clin Pharmacol
Nuki, Colchicine: its mechanism of action and efficacy in crystal-induced inflammation, Curr Rheumatol Reports
Papadopoulos, Patoulias, Teperikidis, Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review, SN Compr Clin Med
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients: a clinical trial study, Mediterr J Rheumatol
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep
Shi, Wang, Shao, COVID-19 infection: the perspectives on immune responses, Cell Death Differ
Soy, Keser, Atagu¨ndu¨z, Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment, Clin Rheumatol
Stewart, Yang, Atkins, Adverse events during oral colchicine use: a systematic review and metaanalysis of randomised controlled trials, Arthritis Res Ther
Tardif, Bouabdallaoui, Pl, Geen plaats voor colchicine in de behandeling van COVID-19, Respir Med
{ 'indexed': {'date-parts': [[2023, 1, 18]], 'date-time': '2023-01-18T05:55:37Z', 'timestamp': 1674021337689}, 'reference-count': 21, 'publisher': 'SAGE Publications', 'license': [ { 'start': { 'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T00:00:00Z', 'timestamp': 1673827200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://journals.sagepub.com/page/policies/text-and-data-mining-license'}], 'funder': [ { 'DOI': '10.13039/501100004160', 'name': 'mazandaran university of medical sciences', 'doi-asserted-by': 'publisher', 'award': ['IRMAZUMS8653']}], 'content-domain': {'domain': ['journals.sagepub.com'], 'crossmark-restriction': True}, 'abstract': '<jats:p> This study was designed to evaluate the effects of colchicine in the improvement of ' 'clinical outcomes of hospitalized COVID-19 patients. This prospective, randomized, ' 'double-blind, placebo-controlled clinical trial was conducted on adult patients (&gt;18\u2009' 'years) with severe COVID-19. The included patients were randomly (1:1) assigned to the ' 'colchicine (2\u2009mg loading dose followed by 0.5\u2009mg twice daily for 7\u2009days) or ' 'placebo group. Both groups received remdesivir and interferon beta-1b. The primary outcome of ' 'the study was to receive clinical response as ordinal scale of 1 or 2. Secondary outcomes ' 'were hospital complications and 28-day mortality. Between February and May 2021, 110 patients ' 'were included and 106 of them were analyzed. Baseline clinical characteristics and ' 'demographics were not significantly different. According to the ordinal scale, 30 patients in ' 'the control group (58.8%) responded to treatment within 7\u2009days, while 35 patients ' '(63.6%) in the colchicine group showed the same response (p\u2009=\u20090.61, odds ratio ' '(OR)\u2009=\u20091.23, 95% CI [0.560–2.68]). On the 14th day, 87.3% of the colchicine group ' '(n\u2009=\u200948) and 82.4% of the control group (n\u2009=\u200942) responded (p\u2009=\u2009' '0.48, OR\u2009=\u20091.47, 95% CI [0.50.3–4.29]. In addition, 28-day mortality, intensive ' 'care unit admission, and hospital duration were not different between the groups (p\u2009' '=\u20090.99, 0.59, 0.06). Diarrhea and nausea were the major side effects dominant in the ' 'colchicine group. Colchicine showed no beneficial effects on clinical improvement and ' 'hospital complications in patients with COVID-19. Moreover, in case of prescription, the ' 'safety concerns of colchicine, specially gastrointestinal side effects, should be taken into ' 'account. </jats:p>', 'DOI': '10.1177/10815589221141815', 'type': 'journal-article', 'created': {'date-parts': [[2023, 1, 17]], 'date-time': '2023-01-17T10:42:57Z', 'timestamp': 1673952177000}, 'page': '108155892211418', 'update-policy': 'http://dx.doi.org/10.1177/sage-journals-update-policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, ' 'placebo-controlled clinical trial', 'prefix': '10.1177', 'author': [ { 'given': 'Hossein', 'family': 'Kasiri', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran ' 'University of Medical Sciences, Sari, Iran'}]}, { 'given': 'Mobin', 'family': 'Ghazaiean', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Medicine, Mazandaran University of Medical Sciences, ' 'Sari, Iran'}]}, { 'given': 'Nima', 'family': 'Rouhani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Infectious Disease, Ibn Sina Medical and ' 'Educational Center, Mazandaran University of Medical Sciences, ' 'Sari, Iran'}]}, { 'given': 'Fahimeh', 'family': 'Naderi-behdani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran ' 'University of Medical Sciences, Sari, Iran'}]}, { 'given': 'Monireh', 'family': 'Ghazaeian', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmaceutical Research Center, Department of Clinical Pharmacy, ' 'Faculty of Pharmacy, Mazandaran University of Medical Sciences, ' 'Sari, Iran'}]}, { 'given': 'Robabeh', 'family': 'Ghodssi-Ghassemabadi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Biostatistics, School of Medical Sciences, Tarbiat ' 'Modares University, Tehran, Iran'}]}], 'member': '179', 'published-online': {'date-parts': [[2023, 1, 16]]}, 'reference': [ { 'key': 'bibr1-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jiph.2020.02.033'}, { 'issue': '19', 'key': 'bibr2-10815589221141815', 'first-page': '1813', 'volume': '338', 'author': 'Madsen LW.', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'bibr3-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.31138/mjr.33.2.232'}, { 'key': 'bibr4-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40495-020-00225-6'}, { 'key': 'bibr5-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2020.13136'}, { 'key': 'bibr6-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11926-008-0036-3'}, { 'key': 'bibr7-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcph.1645'}, { 'key': 'bibr8-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': 'bibr9-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217712'}, { 'key': 'bibr10-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10067-020-05190-5'}, { 'key': 'bibr11-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12967-020-02333-9'}, { 'key': 'bibr12-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.2217/fvl-2020-0310'}, { 'key': 'bibr13-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41418-020-0530-3'}, { 'key': 'bibr14-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0327-4'}, { 'key': 'bibr15-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/rmdopen-2020-001455'}, { 'key': 'bibr16-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0248276'}, { 'key': 'bibr17-10815589221141815', 'first-page': '924', 'volume': '9', 'author': 'Tardif JC', 'year': '2021', 'journal-title': 'Respir Med'}, { 'key': 'bibr18-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00435-5'}, { 'key': 'bibr19-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.reuma.2020.05.001'}, { 'key': 'bibr20-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13075-020-2120-7'}, { 'key': 'bibr21-10815589221141815', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s42399-020-00421-x'}], 'container-title': 'Journal of Investigative Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://journals.sagepub.com/doi/pdf/10.1177/10815589221141815', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://journals.sagepub.com/doi/full-xml/10.1177/10815589221141815', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://journals.sagepub.com/doi/pdf/10.1177/10815589221141815', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 1, 17]], 'date-time': '2023-01-17T10:43:02Z', 'timestamp': 1673952182000}, 'score': 1, 'resource': {'primary': {'URL': 'http://journals.sagepub.com/doi/10.1177/10815589221141815'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 16]]}, 'references-count': 21, 'alternative-id': ['10.1177/10815589221141815'], 'URL': 'http://dx.doi.org/10.1177/10815589221141815', 'relation': {}, 'ISSN': ['1081-5589', '1708-8267'], 'subject': ['General Biochemistry, Genetics and Molecular Biology', 'General Medicine'], 'container-title-short': 'Journal of Investigative Medicine', 'published': {'date-parts': [[2023, 1, 16]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit